irinotecan has been researched along with spc-839 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berard, E; Colosetti, P; Czerucka, D; Dreano, M; Fenouille, N; Griessinger, E; Hofman, P; Imbert, V; Lagadec, P; Mari, M; Nawrot, MP; Peyron, JF; Rousseau, D | 1 |
| Caroli-Bosc, FX; Czerucka, D; Fenouille, N; Grosso, S; Imbert, V; Lagadec, P; Mary, D; Peyron, JF; Pontier-Bres, R; Yunchao, S | 1 |
2 other study(ies) available for irinotecan and spc-839
| Article | Year |
|---|---|
Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Synergism; Female; HT29 Cells; Humans; I-kappa B Kinase; Irinotecan; Mice; Mice, Nude; NF-kappa B; Protein Kinase Inhibitors; Pyrimidines; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Calpain 2-dependent IκBα degradation mediates CPT-11 secondary resistance in colorectal cancer xenografts.
Topics: Animals; Annexin A2; Antineoplastic Agents; Apoptosis; Calpain; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; I-kappa B Proteins; Irinotecan; Mice; Mice, Inbred Strains; Mice, Nude; Neoplasm Transplantation; NF-kappa B; Pyrimidines; S100 Proteins; Transfection; Xenograft Model Antitumor Assays | 2012 |